Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
42.61+0.66 (+1.57%)
At close: 04:00PM EDT
43.22 +0.61 (+1.43%)
After hours: 04:10PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close44.48
Open45.03
Bid42.65 x 1200
Ask42.70 x 800
Day's Range42.62 - 45.81
52 Week Range27.50 - 73.00
Volume844,552
Avg. Volume1,234,812
Market Cap4.148B
Beta (5Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-6.47
Earnings DateApr 26, 2022 - May 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est72.00
  • GlobeNewswire

    Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress

    Accepted abstracts include an oral presentation highlighting quality of life improvements with EMPAVELI® (pegcetacoplan) WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that seven abstracts will be presented at the hybrid European Hematology Association (EHA) Congress to be held June 9-12 in Vienna, Austria. Data to be presented reinforce the robust efficacy and safety prof

  • GlobeNewswire

    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new employees with a grant date of May 2, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. T

  • Zacks

    Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top

    Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.

Advertisement
Advertisement